PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463777
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463777
Gene Cloning Services Market Size and Share Analysis by Service, Application, Gene Type, End User - Global Industry Demand Forecast to 2030
Market Overview
The market value of global gene cloning services is estimated to be USD 3,154.1 million in 2023 and is projected to reach USD 10,019.6 million by 2030, with a Compound Annual Growth Rate (CAGR) of 18.1% during the period from 2024 to 2030.
The rising occurrence of chronic illnesses, the growing need for accurate drugs, and the substantial occurrence of inherited conditions are projected to contribute to the development of the industry. Moreover, the substantial surge in research in the medicinal field because of the rise in spending by governments, the development of the biotechnological sector, and technical improvements in genetics are projected to propel the industry revenue in the coming years.
Nowadays we see a growing trend of a sedentary way of life, which goes with alcohol consumption, increased smoking, terminal fast food, and exercise too rare. The adoption of this unhealthy diet is causing the state of health of people to be even more unhealthy and also the development of many long-term diseases.
Diseases make things worse and serious diseases will be the things that can even end the life of a person. This therefore led to an increase in the need for such methods of treatments that are either more efficient or more effective in curing the disease.
Key Insights
In 2023, the gene synthesis category grips the dominating industry share of 45%.
Its acceptance stems from its extensive application in numerous verticals and the growing research activities globally.
Researchers are progressively using gene synthesis along with techs such as CRISPR genome editing and synthetic biology for enhanced solutions in life sciences.
Gene synthesis can be used in the fields of neurosciences, therapeutic antibody structure development, plant biology, cancer biology, genetics, and biochemistry.
Initially, it is considered a tool pushed to the front for economical tasks of the traditional cloning and molecular biology method that sometimes need time and are expensive.
In 2023, gene therapy grips a leading industry share of 35%.
Its potential lies in its capability to cure previously irredeemable ailments or diseases.
More than 50,000 inherited illnesses caused by gene mutations have been recognized, making gene treatment a promising method.
Understanding protein pathways and gene expression allows for the testing and effectiveness of more therapies.
In 2023, the North American region holds the largest industry share of approximately 55% because of substantial R&D in the biotechnology and pharmaceutical industries.
Reasons contributing to this comprise the high occurrence of chronic illnesses, a strong healthcare system, and acceptance of enhanced technologies.
Top biotechnology businesses and genomic research projects with significant investments are propelling industry development.
Positive perceptions of health and genetic testing to individuals may stimulate research of genomics in medicine to evaluate therapeutic purposes.
Due to the well-established healthcare, general public knowledge, and individual capacity of a modern person to cover the expenses related to treatment, and along with the implementation of gene therapies for cancer, Canada provides the largest market share in North America.
Enhanced healthcare coverage as well as steady improvement of pharmaceutical and biotech industries is going to result in a substantial portion in the forecast. Additionally, rising chronic diseases, and growing gene cloning in diagnostic and drug development, will support Europe in ranking within the top five markets.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by service
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by gene type
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Service (2017-2030)
- 6.3. Market Revenue, by Application (2017-2030)
- 6.4. Market Revenue, by Gene Type (2017-2030)
- 6.5. Market Revenue, by End User (2017-2030)
- 6.6. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Service (2017-2030)
- 7.3. Market Revenue, by Application (2017-2030)
- 7.4. Market Revenue, by Gene Type (2017-2030)
- 7.5. Market Revenue, by End User (2017-2030)
- 7.6. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Service (2017-2030)
- 8.3. Market Revenue, by Application (2017-2030)
- 8.4. Market Revenue, by Gene Type (2017-2030)
- 8.5. Market Revenue, by End User (2017-2030)
- 8.6. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Service (2017-2030)
- 9.3. Market Revenue, by Application (2017-2030)
- 9.4. Market Revenue, by Gene Type (2017-2030)
- 9.5. Market Revenue, by End User (2017-2030)
- 9.6. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Service (2017-2030)
- 10.3. Market Revenue, by Application (2017-2030)
- 10.4. Market Revenue, by Gene Type (2017-2030)
- 10.5. Market Revenue, by End User (2017-2030)
- 10.6. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Service (2017-2030)
- 11.3. Market Revenue, by Application (2017-2030)
- 11.4. Market Revenue, by Gene Type (2017-2030)
- 11.5. Market Revenue, by End User (2017-2030)
- 11.6. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Service (2017-2030)
- 12.3. Market Revenue, by Application (2017-2030)
- 12.4. Market Revenue, by Gene Type (2017-2030)
- 12.5. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Service (2017-2030)
- 13.3. Market Revenue, by Application (2017-2030)
- 13.4. Market Revenue, by Gene Type (2017-2030)
- 13.5. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Service (2017-2030)
- 14.3. Market Revenue, by Application (2017-2030)
- 14.4. Market Revenue, by Gene Type (2017-2030)
- 14.5. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Service (2017-2030)
- 15.3. Market Revenue, by Application (2017-2030)
- 15.4. Market Revenue, by Gene Type (2017-2030)
- 15.5. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Service (2017-2030)
- 16.3. Market Revenue, by Application (2017-2030)
- 16.4. Market Revenue, by Gene Type (2017-2030)
- 16.5. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Service (2017-2030)
- 17.3. Market Revenue, by Application (2017-2030)
- 17.4. Market Revenue, by Gene Type (2017-2030)
- 17.5. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Service (2017-2030)
- 18.3. Market Revenue, by Application (2017-2030)
- 18.4. Market Revenue, by Gene Type (2017-2030)
- 18.5. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Service (2017-2030)
- 19.3. Market Revenue, by Application (2017-2030)
- 19.4. Market Revenue, by Gene Type (2017-2030)
- 19.5. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Service (2017-2030)
- 20.3. Market Revenue, by Application (2017-2030)
- 20.4. Market Revenue, by Gene Type (2017-2030)
- 20.5. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Service (2017-2030)
- 21.3. Market Revenue, by Application (2017-2030)
- 21.4. Market Revenue, by Gene Type (2017-2030)
- 21.5. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Service (2017-2030)
- 22.3. Market Revenue, by Application (2017-2030)
- 22.4. Market Revenue, by Gene Type (2017-2030)
- 22.5. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Service (2017-2030)
- 23.3. Market Revenue, by Application (2017-2030)
- 23.4. Market Revenue, by Gene Type (2017-2030)
- 23.5. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Service (2017-2030)
- 24.3. Market Revenue, by Application (2017-2030)
- 24.4. Market Revenue, by Gene Type (2017-2030)
- 24.5. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Service (2017-2030)
- 25.3. Market Revenue, by Application (2017-2030)
- 25.4. Market Revenue, by Gene Type (2017-2030)
- 25.5. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Service (2017-2030)
- 26.3. Market Revenue, by Application (2017-2030)
- 26.4. Market Revenue, by Gene Type (2017-2030)
- 26.5. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Service (2017-2030)
- 27.3. Market Revenue, by Application (2017-2030)
- 27.4. Market Revenue, by Gene Type (2017-2030)
- 27.5. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Service (2017-2030)
- 28.3. Market Revenue, by Application (2017-2030)
- 28.4. Market Revenue, by Gene Type (2017-2030)
- 28.5. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Thermo Fisher Scientific Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Genscript Biotech Corporation
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Eurofins Scientific SE
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Charles River Laboratories International Inc.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Takara Bio Inc.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Creative Biogene
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Synbio Technologies
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Aragen Life Sciences Ltd.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Sino Biological Inc.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
- 30.10. Curia Global Inc.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
